|
1
|
Bandera AI, Sebaratnam DF, Wargon O and
Wong LF: Infantile hemangioma. Part 1: Epidemiology, pathogenesis,
clinical presentation and assessment. J Am Acad Dermatol.
85:1379–1392. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Satterfield KR and Chambers CB: Current
treatment and management of infantile hemangiomas. Surv Ophthalmol.
64:608–618. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nazemian S, Sharif S and Childers ELB:
Infantile hemangioma: A common lesion in a vulnerable population.
Int J Environ Res Public Health. 20:55852023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee JC, Modiri O, England RW, Shawber CJ
and Wu JK: Propranolol therapy in infantile hemangioma: It is not
just about the beta. Plast Reconstr Surg. 147:875–885. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hasbani DJ and Hamie L: Infantile
hemangiomas. Dermatol Clin. 40:383–392. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Song J, Zhang J, Wang J, Wang J, Guo X and
Dong W: β1 integrin mediates colorectal cancer cell proliferation
and migration through regulation of the Hedgehog pathway. Tumour
Biol. 36:2013–2021. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sebaratnam DF, Bandera AL, Wong LF and
Wargon O: Infantile hemangioma. Part 2: Management. J Am Acad
Dermatol. 85:1395–1404. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Muñoz-Garza FZ, Ríos M, Roé-Crespo E,
Bernabeu-Wittel J, Montserrat-García MT, Puig L, Puig L, Gich I and
Baselga E: Efficacy and safety of topical timolol for the treatment
of infantile hemangioma in the early proliferative stage: A
randomized clinical trial. JAMA Dermatol. 157:583–587. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Williams M, Cheng YY, Blenkiron C and Reid
G: Exploring mechanisms of MicroRNA downregulation in cancer.
Microrna. 6:2–16. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Diener C, Keller A and Meese E: Emerging
concepts of miRNA therapeutics: From cells to clinic. Trends Genet.
38:613–626. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang T, Qian Y, Yuan C, Wu Y, Qian H, Lu
H, Hu C and Li W: Propranolol suppresses proliferation and
migration of HUVECs through regulation of the miR-206/VEGFA axis.
Biomed Res Int. 2021:76291762021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Su C, Mo J, Dong S, Liao Z, Zhang B and
Zhu P: Integrinβ-1 in disorders and cancers: molecular mechanisms
and therapeutic targets. Cell Commun Signal. 22:712024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li S, Sampson C, Liu C, Piao HL and Liu
HX: Integrin signaling in cancer: Bidirectional mechanisms and
therapeutic opportunities. Cell Commun Signal. 21:2662023.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xie J, Guo T, Zhong Z, Wang N, Liang Y,
Zeng W, Liu S, Chen Q, Tang X, Wu H, et al: ITGB1 Drives
hepatocellular carcinoma progression by modulating cell cycle
process through PXN/YWHAZ/AKT pathways. Front Cell Dev Biol.
9:7111492021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gu W, Sun H, Zhang M, Mo S, Tan C, Ni S,
Yang Z, Wang Y, Sheng W and Wang L: ITGB1 as a prognostic biomarker
correlated with immune suppression in gastric cancer. Cancer Med.
12:1520–1531. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao FY, Li XT, Xu K, Wang RT and Guan XX:
c-MYC mediates the crosstalk between breast cancer cells and tumor
microenvironment. Cell Commun Signaling. 21:282023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vallée A and Lecarpentier Y: Crosstalk
between peroxisome proliferator-activated receptor gamma and the
canonical WNT/β-catenin pathway in chronic inflammation and
oxidative stress during carcinogenesis. Front Immunol. 9:7452018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Isagulieva AK, Soshnikova NV and Shtil AA:
Inhibition of the c-Myc oncogene by the aureolic acid group
antibiotics. Dokl Biochem Biophys. 500:308–311. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang R, Xiao X, Fu Y, Zhang C, Zhu X and
Gao Y: ITGB1-DT facilitates lung adenocarcinoma progression via
forming a positive feedback loop with ITGB1/Wnt/β-Catenin/MYC.
Front Cell Dev Biol. 9:6312592021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Song F, Chen FY, Wu SY, Hu B, Liang XL,
Yang HQ, Cheng JW, Wang PX, Guo W, Zhou J, et al: Mucin 1 promotes
tumor progression through activating WNT/β-catenin signaling
pathway in intrahepatic cholangiocarcinoma. J Cancer. 12:6937–6947.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin CH, Liao CC, Chen MY and Chou TY:
Feedback regulation of O-GlcNAc transferase through translation
control to maintain intracellular O-GlcNAc homeostasis. Int J Mol
Sci. 22:34632021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ferrer CM, Sodi VL and Reginato MJ:
O-GlcNAcylation in cancer biology: Linking metabolism and
signaling. J Mol Biol. 428:3282–3294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu D, Jin J, Qiu Z, Liu D and Luo H:
Functional analysis of O-GlcNAcylation in cancer metastasis. Front
Oncol. 10:5852882020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Luanpitpong S, Rodboon N, Samart P,
Vinayanuwattikun C, Klamkhlai S, Chanvorachote P, Rojanasakul Y and
Issaragrisil S: A novel TRPM7/O-GlcNAc axis mediates tumour cell
motility and metastasis by stabilising c-Myc and caveolin-1 in lung
carcinoma. Br J Cancer. 123:1289–1301. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang T, Yang J, Yang H, Chen W, Ji K, Xu
Y and Yu L: SLC35B4 stabilizes c-MYC protein by O-GlcNAcylation in
HCC. Front Pharmacol. 13:8510892022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang K, Qiu T, Gong X, Zhou J, Lan Y, Chen
S and Ji Y: Integrated nontargeted and targeted metabolomics
analyses amino acids metabolism in infantile hemangioma. Front
Oncol. 13:11323442023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Horita M, Farquharson C and Stephen LA:
The role of miR-29 family in disease. J Cell Biochem. 122:696–715.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qi S, Xu L, Han Y, Chen H and Cheng A:
miR-29a-3p mitigates the development of osteosarcoma through
modulating IGF1 mediated PI3k/Akt/FOXO3 pathway by activating
autophagy. Cell Cycle. 21:1980–1995. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cao Y, Wen H, Leng C and Feng S: MiR-29a
mediates the apoptotic effects of TNF-α on endothelial cells
through inhibiting PI3K/AKT/BCL-2 axis. J Biochem Mol Toxicol.
38:e235982024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu F, Wu Q, Dong Z and Liu K: Integrins
in cancer: Emerging mechanisms and therapeutic opportunities.
Pharmacol Ther. 247:1084582023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang J, Zhou P, Wang X, Yu Y, Zhu G, Zheng
L, Xu Z, Li F, You Q, Yang Q, et al: Rab25 promotes erlotinib
resistance by activating the β1 integrin/AKT/β-catenin pathway in
NSCLC. Cell Prolif. 52:e125922019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zuo XX, Yang Y, Zhang Y, Zhang ZG, Wang XF
and Shi YG: Platelets promote breast cancer cell MCF-7 metastasis
by direct interaction: Surface integrin α2β1-contacting-mediated
activation of Wnt-β-catenin pathway. Cell Commun Signal.
17:1422019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yasumizu Y, Rajabi H, Jin C, Hata T,
Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, et al: MUC1-C
regulates lineage plasticity driving progression to neuroendocrine
prostate cancer. Nat Commun. 11:3382020. View Article : Google Scholar : PubMed/NCBI
|
